Halozyme Therapeutics Inc. (HALO) reported Q4 2025 revenue of $451.8 million, up 51.6% year-over-year and slightly above the consensus revenue estimate of $446.7 million by about $5.0 million (roughly 1.1%).
Key income statement highlights:
Cash flow and balance sheet:
Market reaction: the stock was down 4.31% since market close.
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Halozyme Therapeutics Inc. Insider Trading Activity
Halozyme Therapeutics Inc. insiders have traded $HALO stock on the open market 51 times in the past 6 months. Of those trades, 0 have been purchases and 51 have been sales.
Here’s a breakdown of recent trading of $HALO stock by insiders over the last 6 months:
- HELEN TORLEY (PRESIDENT AND CEO) has made 0 purchases and 38 sales selling 246,569 shares for an estimated $17,919,728.
- NICOLE LABROSSE (SVP, CHIEF FINANCIAL OFFICER) has made 0 purchases and 4 sales selling 22,227 shares for an estimated $1,687,851.
- BERNADETTE CONNAUGHTON has made 0 purchases and 8 sales selling 10,829 shares for an estimated $782,033.
- CORTNEY CAUDILL (SVP, CHIEF OPERATING OFFICER) sold 4,263 shares for an estimated $277,904
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Halozyme Therapeutics Inc. Hedge Fund Activity
We have seen 292 institutional investors add shares of Halozyme Therapeutics Inc. stock to their portfolio, and 345 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC added 1,842,956 shares (+inf%) to their portfolio in Q4 2025, for an estimated $124,030,938
- D. E. SHAW & CO., INC. added 1,631,571 shares (+160.1%) to their portfolio in Q3 2025, for an estimated $119,659,417
- UBS GROUP AG removed 1,580,108 shares (-53.6%) from their portfolio in Q4 2025, for an estimated $106,341,268
- MACQUARIE GROUP LTD removed 1,546,185 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $104,058,250
- VOLORIDGE INVESTMENT MANAGEMENT, LLC added 1,057,902 shares (+inf%) to their portfolio in Q3 2025, for an estimated $77,586,532
- NORGES BANK added 1,039,354 shares (+120.1%) to their portfolio in Q4 2025, for an estimated $69,948,524
- MIZUHO MARKETS AMERICAS LLC added 926,526 shares (+270.8%) to their portfolio in Q4 2025, for an estimated $62,355,199
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Halozyme Therapeutics Inc. Analyst Ratings
Wall Street analysts have issued reports on $HALO in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- TD Cowen issued a "Buy" rating on 01/08/2026
- HC Wainwright & Co. issued a "Buy" rating on 12/19/2025
- Benchmark issued a "Buy" rating on 09/24/2025
To track analyst ratings and price targets for Halozyme Therapeutics Inc., check out Quiver Quantitative's $HALO forecast page.
Halozyme Therapeutics Inc. Price Targets
Multiple analysts have issued price targets for $HALO recently. We have seen 8 analysts offer price targets for $HALO in the last 6 months, with a median target of $84.5.
Here are some recent targets:
- Brendan Smith from TD Cowen set a target price of $90.0 on 01/08/2026
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $90.0 on 12/19/2025
- Graig Suvannavejh from Goldman Sachs set a target price of $56.0 on 11/18/2025
- Jason Butler from Citizens set a target price of $92.0 on 11/04/2025
- Jessica Fye from JP Morgan set a target price of $65.0 on 10/27/2025
- Vikram Purohit from Morgan Stanley set a target price of $79.0 on 10/20/2025
- David Risinger from Leerink Partners set a target price of $70.0 on 10/14/2025
